These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 27598304)

  • 1. Proteomics discovery of chemoresistant biomarkers for ovarian cancer therapy.
    Deng J; Wang L; Ni J; Beretov J; Wasinger V; Wu D; Duan W; Graham P; Li Y
    Expert Rev Proteomics; 2016 Oct; 13(10):905-915. PubMed ID: 27598304
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proteomics discovery of radioresistant cancer biomarkers for radiotherapy.
    Chang L; Graham P; Hao J; Bucci J; Malouf D; Gillatt D; Li Y
    Cancer Lett; 2015 Dec; 369(2):289-97. PubMed ID: 26427840
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cancer biomarker discovery and translation: proteomics and beyond.
    Hristova VA; Chan DW
    Expert Rev Proteomics; 2019 Feb; 16(2):93-103. PubMed ID: 30556752
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular insights into cancer drug resistance from a proteomics perspective.
    An Y; Zhou L; Huang Z; Nice EC; Zhang H; Huang C
    Expert Rev Proteomics; 2019 May; 16(5):413-429. PubMed ID: 30925852
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mass spectrometry-assisted gel-based proteomics in cancer biomarker discovery: approaches and application.
    Huang R; Chen Z; He L; He N; Xi Z; Li Z; Deng Y; Zeng X
    Theranostics; 2017; 7(14):3559-3572. PubMed ID: 28912895
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mass spectrometry-based clinical proteomics: head-and-neck cancer biomarkers and drug-targets discovery.
    Matta A; Ralhan R; DeSouza LV; Siu KW
    Mass Spectrom Rev; 2010; 29(6):945-61. PubMed ID: 20945361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proteomics approach to identify biomarkers for upper gastrointestinal cancer.
    Harada K; Mizrak Kaya D; Shimodaira Y; Song S; Baba H; Ajani JA
    Expert Rev Proteomics; 2016 Nov; 13(11):1041-1053. PubMed ID: 27718753
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proteogenomic studies on cancer drug resistance: towards biomarker discovery and target identification.
    Fu S; Liu X; Luo M; Xie K; Nice EC; Zhang H; Huang C
    Expert Rev Proteomics; 2017 Apr; 14(4):351-362. PubMed ID: 28276747
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proteomic identification of paclitaxel-resistance associated hnRNP A2 and GDI 2 proteins in human ovarian cancer cells.
    Lee DH; Chung K; Song JA; Kim TH; Kang H; Huh JH; Jung SG; Ko JJ; An HJ
    J Proteome Res; 2010 Nov; 9(11):5668-76. PubMed ID: 20858016
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Proteomics and biomarkers for detection of ovarian cancer].
    Kacerovský M; Tambor V; Lenco J; Tosner J
    Ceska Gynekol; 2009 Jun; 74(3):163-70. PubMed ID: 19642513
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mining the fecal proteome: from biomarkers to personalised medicine.
    Jin P; Wang K; Huang C; Nice EC
    Expert Rev Proteomics; 2017 May; 14(5):445-459. PubMed ID: 28361558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proteomics and biomarkers for ovarian cancer diagnosis.
    Zhang B; Barekati Z; Kohler C; Radpour R; Asadollahi R; Holzgreve W; Zhong XY
    Ann Clin Lab Sci; 2010; 40(3):218-25. PubMed ID: 20689132
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical translation of MS-based, quantitative plasma proteomics: status, challenges, requirements, and potential.
    Percy AJ; Byrns S; Pennington SR; Holmes DT; Anderson NL; Agreste TM; Duffy MA
    Expert Rev Proteomics; 2016 Jul; 13(7):673-84. PubMed ID: 27341553
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent mass spectrometry-based proteomics for biomarker discovery in lung cancer, COPD, and asthma.
    Fujii K; Nakamura H; Nishimura T
    Expert Rev Proteomics; 2017 Apr; 14(4):373-386. PubMed ID: 28271730
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Urinary biomarkers in prostate cancer detection and monitoring progression.
    Wu D; Ni J; Beretov J; Cozzi P; Willcox M; Wasinger V; Walsh B; Graham P; Li Y
    Crit Rev Oncol Hematol; 2017 Oct; 118():15-26. PubMed ID: 28917266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The discovery of protein biomarkers in pre-eclampsia: the promising role of mass spectrometry.
    Dahabiyeh LA
    Biomarkers; 2018 Nov; 23(7):609-621. PubMed ID: 29737875
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oncoproteomics: current trends and future perspectives.
    Cho WC; Cheng CH
    Expert Rev Proteomics; 2007 Jun; 4(3):401-10. PubMed ID: 17552924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proteomics and metabolomics in biomarker discovery for cardiovascular diseases: progress and potential.
    Tuñón J; Barbas C; Blanco-Colio L; Burillo E; Lorenzo Ó; Martín-Ventura JL; Más S; Rupérez FJ; Egido J
    Expert Rev Proteomics; 2016 Sep; 13(9):857-71. PubMed ID: 27459711
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mass spectrometry based translational proteomics for biomarker discovery and application in colorectal cancer.
    Ma H; Chen G; Guo M
    Proteomics Clin Appl; 2016 Apr; 10(4):503-15. PubMed ID: 26616366
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective applications of ultrahigh resolution proteomics in clinical mass spectrometry.
    Ruhaak LR; van der Burgt YE; Cobbaert CM
    Expert Rev Proteomics; 2016 Dec; 13(12):1063-1071. PubMed ID: 27798968
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.